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Abstract: Use of nanomaterials in manufactured consumer products is a rapidly expanding 
industry and potential toxicities are just beginning to be explored. Combustion-generated 
multiwall carbon nanotubes (MWCNT) or nanoparticles are ubiquitous in non-manufacturing 
environments and detectable in vapors from diesel fuel, methane, propane, and natural gas. 
In experimental animal models, carbon nanotubes have been shown to induce granulomas 
or other inflammatory changes. Evidence suggesting potential involvement of carbon 
nanomaterials in human granulomatous disease, has been gathered from analyses of dusts 
generated in the World Trade Center disaster combined with epidemiological data showing a 
subsequent increase in granulomatous disease of first responders. In this review we will discuss 
evidence for similarities in the pathophysiology of carbon nanotube-induced pulmonary 
disease in experimental animals with that of the human granulomatous disease, sarcoidosis. 
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1. Granulomatous Lung Disease 
1.1. Background 
Granulomatous diseases represent a world-wide health problem. Granuloma formation is a host 
response designed to sequester and destroy an injurious substance or infectious organism (reviewed in [1]). 
OPEN ACCESS
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The granuloma itself is a complex, multicellular structure generated by components of the innate 
immune system (reviewed in [2]). Granulomas may form in the lung in response to environmental 
stimuli of a broad nature, including intracellular pathogens (mycobacteria, fungi), chemically inert 
materials such as silica, beryllium, or talc, and organic antigens as in hypersensitivity pneumonitis. 
Initial formation of the granuloma involves release of a large repertoire of pro-inflammatory mediators 
designed to recruit neutrophils and other cells into the area. If neutrophils cannot destroy the substance, 
it is phagocytized by macrophages which release additional pro-inflammatory cytokines and 
chemokines. This cytokine storm recruits T cells, natural killer (NK) cells, and dendritic cells so that 
any digested antigenic components of the substance can be presented to activate an adaptive immune 
response [3]. Failure of macrophages to destroy the substance within the granuloma results in a chronic 
inflammatory pulmonary condition that can have significant morbidity. Chronic granulomatous disease 
can occur in the presence or absence of a detectible adaptive immune response. 
1.2. Sarcoidosis: Characterization 
Sarcoidosis is a multi-organ, inflammatory granulomatous disease thought to occur as a result  
of exposure to an unidentified, poorly soluble environmental antigen(s). The antigenic substance 
triggers a host response which is related to genetic/epigenetic susceptibility factors [4]. As discussed 
below, many potential putative sarcoidosis “antigens” have been identified, but none has been clearly 
confirmed as a direct cause of the disease. The diagnosis of sarcoidosis is usually established by 
clinical history, a biopsy revealing non-caseating granulomas with adjacent inflammatory cell infiltrates, 
and negative studies for active infection. Currently there are no definitive biomarkers available  
for therapeutic targets or for assistance in the clinical evaluation of sarcoidosis patient prognosis, 
responses to therapy, or disease management. 
1.3. Sarcoidosis: Epidemiology and Potential Etiology 
The prevalence and incidence of sarcoidosis varies by ethnicity and sex. In the United States,  
the adjusted annual incidence is roughly three times higher in African-Americans than in white 
Americans [5,6]. Sarcoidosis is more common in females than in males by a ratio of less than two  
to one [7]. The prevalence of sarcoidosis also appears to vary in different geographic locations [6,8]. 
Several studies have reported microbial antigens (e.g., mycobacterium, propionibacterium acnes)  
in sarcoidosis tissue or lung, and blood cell reactivity to antigen challenge in vitro [9–15]. However, 
some studies have found similar carriage rates of organisms suspected to cause sarcoidosis in control 
subjects without disease [16]. In contrast, other studies have not confirmed the presence of potential 
sarcoidosis pathogens in sarcoidosis subjects [17,18]. 
Multiple environmental risk factors have been linked to sarcoidosis, including dose-related 
exposure to wood-burning stoves, fireplaces, and firefighting [4,19–22]. The atmosphere of such 
environmental conditions might well harbor combustion-generated contaminants composed of carbon 
nanotubes. Related to these findings, the incidence of “sarcoidosis-like” pulmonary granulomatous 
disease was reported to be increased in New York City Fire Department workers who were involved in 
the September 2001 World Trade Center (WTC) disaster where inhalation exposure to combustion 
materials was “intense” [23,24]. More recent follow-ups of some 20,000 WTC responders have 
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detected sarcoidosis-like granulomatous disease at higher levels than expected in non-firefighting 
individuals as well [25]. Of interest was the observation that carbon nanotubes of various sizes and 
lengths were present in WTC dust samples and in lung tissues of affected exposed individuals [26]. 
Extensive analyses of dusts/aerosols generated by the WTC collapse resulted in four major categories 
of components: (1) particulate matter (calcium carbonate and silica) and fibers (asbestos, glass, 
gypsum); (2) organic pollutants including polycyclic aromatic hydrocarbons; (3) gases (carbon dioxide, 
hydrogen sulfide, diesel exhaust fumes, combustion byproducts), and (4) heavy metals [24,27]. Many 
of these components such as particulate matter, fibers, and combustion byproducts have been previously 
associated with cases of sarcoidosis-like disease [24]. Other materials known to produce granulomatous 
reactions such as beryllium, zirconium, or tungsten, were not detectable in WTC dusts [27]. Thus, 
while WTC dust exposure has been clearly linked to increased incidence of respiratory disease [28], 
the identity of WTC dust component(s) responsible for increased cases of sarcoidosis-like granulomatous 
disease remains unknown. Despite the WTC studies and other large epidemiologic and genetic studies, 
no definitive etiology for sarcoidosis has emerged [29–31]. 
2. Animal Models of Carbon Nanotube-Mediated Lung Disease 
2.1. Effects of Carbon Nanotubes 
While nanomaterials such as carbon nanotubes have great potential in fields such as drug delivery 
and disease imaging, standardized means to determine potential toxicities have not yet been 
established (reviewed in [32,33]). Carbon nanotubes represent an arrangement of C60 atoms in an 
elongated cylindrical structure [34]. Interestingly, the history of carbon nanotube discovery is a 
complex tale which may go back well over a century. As colorfully described by Monthioux and 
Kuznetsov [35] the first mention of such structures may have appeared in Russia, in a 1952 volume of 
the Journal of Physical Chemistry. Not until 1993, however, were preparations of single wall carbon 
nanotubes (SWCNT) first detailed by two different investigative groups [35]. SWCNT can be massed 
into multi-wall carbon nanotubes (MWCNT) [34]. Outside of manufacturing, combustion-generated 
MWCNT and other carbon nanoparticles are ubiquitous within the environment, and have been 
detected in vapors from diesel fuel, methane, propane, and natural gas (reviewed in [36]). Thus, the 
importance and impact of carbon particles in our environment might be underestimated as a causative 
agent and/or factor involved in the development of respiratory illnesses. 
Granulomatous inflammation and fibrosis have been reported in rodent models as a response  
to intratracheal administration of SWCNT or MWCNT [37–39]. Several factors have been cited  
as contributors to these findings. Pulmonary granulomatous changes have been associated with large 
agglomerates or aggregates of carbon nanotubes [40–42]. A comparative study of lung tissues in 
inhalation versus instillation reported smaller particle size and diminished pulmonary inflammation 
with inhalation [43]. The authors suggested that differences might be due to the reduced size and 
aggregation of inhaled carbon nanotubes. However, investigations carried out to determine long-term 
effects of inhalation versus instillation have demonstrated similar results with both techniques [44,45]. 
In animals receiving dispersed carbon nanotubes, granulomatous structures have not been observed, 
although increased collagen disposition was detected indicative of a fibrotic response [41,46]. 
Nanomaterials 2014, 4 511 
 
Carbon nanotubes have also been implicated in triggering inflammasome formation [47–49]. 
Inflammasomes are part of innate immunity and consist of large intracellular protein complexes that 
regulate proteolytic activation of the proinflammatory cytokines, IL-1β and IL-18 [50,51]. These 
structures can be activated by microbial triggers as well as non-microbial materials such as asbestos 
and silica [52]. Inflammasome activation is now recognized as a contributor to a number of chronic 
lung diseases such as idiopathic pulmonary fibrosis, chronic obstructive lung disease, and asthma [51]. 
The physical and chemical properties of carbon nanotubes strongly influence pulmonary toxicity. 
Metal contaminants in commercial carbon nanotube preparations have been implicated in nanotube 
toxicity [53]. Hamilton et al. [47] presented both in vitro and in vivo results suggesting that 
inflammatory responses increased with MWCNT diameter and length. This group also found that 
nickel contamination of nanotubes activated inflammasomes, exacerbated lung pathology and promoted 
release of pro-inflammatory cytokines from alveolar macrophages [47]. Other properties of carbon 
nanotubes associated with inflammasome formation and toxicity included double-walled [49]  
and long-needle-like structures [48]. In contrast, modification of carbon nanotubes with polymer 
coatings [54] or other biocompatible materials has been reported to reduce pulmonary toxicity 
(summarized in [55,56]). 
Currently, there is ample evidence that carbon nanotubes provoke pulmonary innate immune  
and inflammatory responses [37–39,48,49], but not adaptive immune responses (reviewed in [57]). 
Results of MWCNT interaction with existing immune system adaptive responses, however, are 
controversial. Inhalation of MWCNT (0.3–5 mg/m3) did not cause significant pulmonary changes but 
did increase TGFβ levels in bronchoalveolar lavage fluid which when applied in vitro to splenocytes 
from untreated mice, suppressed T cell activity [58]. In another inhalation model, Staal et al. [59] 
observed decreased allergen-specific IgE responses in sensitized animals. In contrast, Ronzani et al. [60], 
reported that instilled MWCNT elevated Th2 responses in a house dust mite allergy model. Finally, 
Ryman-Rasmussen et al. [61] found no significant pulmonary changes after MWCNT inhalation  
(100 mg/m3) except in ovalbumin-sensitized animals challenged with antigen. MWCNT treatment then 
increased pulmonary fibrosis and levels of the fibroblast growth factor, PDGF-AA, but had no effects 
on TGFβ or IL-13. These studies suggest that complications in both innate and adaptive immune 
functions may occur after exposure to carbon nanotubes. 
2.2. The MWCNT-Induced Chronic Granuloma Model 
Our major goal has been to improve understanding of sarcoidosis pathophysiology. The relatively 
recent reports of carbon nanotubes in environments favoring sarcoidosis incidence has been the 
impetus for us to develop a model of MWCNT-mediated lung disease that might have applicability to 
sarcoidosis. To our knowledge, no other MWCNT models have been used to study sarcoidosis. This 
model has proven to be extremely interesting with many pathologic changes identical to those found  
in sarcoidosis lung. Because most granulomatous diseases are chronic, and inciting factors may be 
unknown, there are no ideal animal models with which to investigate mechanisms of persistent 
granulomatous inflammation. Our first report described a model in which instilled MWCNT led to 
granulomatous lung inflammation persisting up to 90 days [62]. The long-term chronicity of this 
carbon nanotube granuloma model is relevant to the exploration of mechanisms in human chronic 
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granulomatous disease. Previously, major findings related to granulomatous inflammation were 
derived from studies using an acute murine granuloma model in which antigen-bound sepharose beads 
were injected intravenously into pre-sensitized animals [63,64]. However, such models are limited in 
that granulomatous inflammation forms and resolves within 14–20 days. Also of consideration was the 
delivery route, a tail vein injection of antigen bound-sepharose beads that lodged in the pulmonary 
circulation rather than directly in the alveolar space. 
Dosage of reagent is problematic in all animal disease models particularly in the case of sarcoidosis 
where the inciting antigen(s), mode of induction, and minimum dose exposure have not been established 
for the human disease. Moreover, although murine models are ubiquitously studied, many basic 
biological differences exist in both the innate and adaptive immune responses of mice and man [65]. 
Further, pulmonary disease models must also take into account differences in murine and human 
bronchoalveolar lavage fluid proteins [66]. Despite these problems, murine models of pulmonary 
disease such as the sepharose bead granuloma model mentioned above, have provided valuable data on 
inflammatory granuloma formation [63,67]. 
The MWCNT preparation used in our model exhibited a dominant range of nanotube diameters 
from 20 to 40 nm and a net metal catalyst (Fe) content of less than 1.0% [62]. MWCNT (25–100 μg) 
were administered as a bolus in a 35% surfactant-saline solution via oropharyngeal instillation.  
The dosage we selected was within the range inducing granulomas in a study by Lam et al. [68] using 
intratracheally administered SWCNT. Inhalation studies have demonstrated that exposure of rats  
to aerosols containing 0.1 mg/m3 MWCNT can yield pulmonary granulomatous inflammation [69]. 
When compared to an aerosol delivery method, however, retropharyngeal instillation may be superior 
as it achieves full and consistent delivery, with decreased variability between exposures [43,67]. In our 
model, small granulomatous reactions surrounding MWCNT aggregates were detectable by 10 days 
post instillation with larger reactions persisting for up to 90 days. Bronchoalveolar lavage (BAL)  
of mice revealed MWCNT within alveolar macrophages [62]. 
The major goal in the initial studies of our chronic MWCNT model was to document pathways 
involved in granuloma formation by analyzing potential mediators in granuloma/non-granuloma lung 
tissues and BAL cells. Granulomatous foci and non-granulomatous tissues were collected by laser 
capture microdissection (LCM) for mRNA quantitation. Protein expression in lung tissues or BAL 
cells was evaluated by immunohistochemistry. Results showed elevated expression of osteopontin,  
a cytokine reported to be critical for granuloma formation [70], in granulomatous tissues and in BAL 
cells. Other granuloma-promoting factors found to be elevated were cell adhesion molecules (integrins) 
which are necessary for the fusion of macrophages into multinucleated giant cells within the 
granuloma structure [71]. Similarly, matrix metalloproteinases (MMPs) such as MMP-12 were also 
elevated in granulomatous tissue and in BAL cells. MMP-12 is a contributor to lung remodeling and 
targets elastin [72]. Overexpression has been reported to increase granuloma size in experimental 
animals [73]. Elevated MMP12 was also noted in a SWCNT model showing granulomas [74]. In our 
model, we also observed a concomitant decrease in Tissue Inhibitor of MMPs (TIMP)-3, an inhibitor 
of MMP-12 [75], suggesting that MMP-12 activity was unopposed by tissue inhibitors. These findings 
documented the formation of well-organized granulomas with time-related increases in granuloma size 
and mediator expression. 
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2.3. Parallel Findings in the MWCNT Model and Sarcoidosis 
A review of selective findings from the chronic MWCNT granuloma model reveals many 
pathophysiologic similarities to human sarcoidosis (Table 1). With respect to granuloma formation, 
osteopontin and MMP-12 elevations noted in the MWCNT model have also been reported as 
characteristics of sarcoidosis granulomatous tissues [76,77]. 
Table 1. Comparative findings in the multiwall carbon nanotube (MWCNT) chronic 
granuloma model and human sarcoidosis. 
Mediators/Regulators of  
Inflammation or Damage 
Pulmonary Findings 
MWCNT Model Sarcoidosis 
Osteopontin Granuloma tissue; BAL * cells and fluids, [62] Granuloma tissue [76] 
MMP-12 
Granuloma tissue, BAL * cells [62].  
Lung tissue [74] 
Granuloma tissue [77] 
CCL2 (MCP-1) Granuloma tissue [62]. Lung tissue [74] BAL * fluids [78,79] 
CCL5 (Rantes) BAL * cells (unpublished data) BAL * fluids [78,79] 
TNFα Granuloma tissue [62] Trans-bronchial biopsy tissues [80] 
IFN-γ Granuloma tissue; BAL * cells [81] Granuloma tissue [82]; BAL * cells [83] 
PPARγ Alveolar macrophages [81] Alveolar macrophages [84] 
Twist1 Alveolar macrophages [85] Alveolar macrophages [85] 
Note: * Bronchoalveolar Lavage. 
A survey of pro-inflammatory cytokines and chemokines in the MWCNT model also demonstrated 
close similarities with sarcoidosis lung (Table 1). Elevated TNFα and the chemokine CCL2 (MCP-1) 
were noted in murine granulomatous tissue at 60 and 90 days post MWCNT instillation [62]. More 
recent studies in progress have also detected CCL5 (Rantes) production at 60 days after MWCNT 
instillation (unpublished data). All three of these pro-inflammatory mediators are known to be elevated 
in sarcoidosis granulomatous tissue and BAL cells [78,80] and are indicators of NF-κB activation 
which we have documented previously in sarcoidosis [84]. 
In our next study of the MWCNT model, we examined the role of the transcription factor, 
peroxisome proliferator-activated receptor gamma (PPARγ). While this transcription factor is a critical 
regulator of lipid and glucose metabolism, PPARγ also exerts negative effects on many pro-inflammatory 
genes [86]. Our previous studies had established that PPARγ binding activity and expression were 
deficient in alveolar macrophages from sarcoidosis patients [84]. Our first aim in the MWCNT model 
was to determine whether MWCNT instillation would also cause a reduction in alveolar macrophage 
PPARγ from wild-type mice. All studies were terminated at 60 days after MWCNT instillation. Results 
from wild-type mice proved to be virtually identical to those we observed in sarcoidosis, with alveolar 
macrophages showing significantly depressed PPARγ activity and expression [81]. Our second aim in 
the study was to determine whether pre-existing PPARγ deficiency would affect production of 
granuloma structures and inflammatory mediators. To this end, we utilized macrophage-specific 
PPARγ KO conditional mice. Results from MWCNT-instilled PPARγ KO mice demonstrated a more 
extensive granuloma formation and higher levels of osteopontin and pro-inflammatory cytokines  
(IFN-γ, CCL2) in granulomatous tissues and BAL cells than in similarly treated wild-type mice [81]. 
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Thus results suggested that PPARγ functions as a negative regulator of chronic granulomatous 
inflammation in the lung. 
In our latest publication, we utilized the MWCNT model to explore expression of the Twist1 
transcription factor in alveolar macrophages. Initially, we had carried out gene array analysis of BAL 
cells in sarcoidosis patients and healthy human controls to ascertain patterns of macrophage activation 
phenotypes M1 and M2 [85]. Findings showed a predominantly M1 phenotype in sarcoidosis alveolar 
macrophages together with a significant increase in Twist1 gene expression. Twist1 has been shown  
to be a regulator of embryonic mesenchymal development [87] but its possible function in alveolar 
macrophages has not been ascertained. Gene array data were confirmed by quantitative mRNA 
analysis of sarcoidosis BAL cells and protein expression was found to be localized to alveolar 
macrophages. To determine whether Twist1 expression could be a general marker of inflammatory 
alveolar macrophages, wild-type and macrophage-specific PPARγ KO mice received instillations  
of MWCNT and were analyzed 60 days later. Results were similar to findings in sarcoidosis: Twist1 
protein was elevated in both wild-type and PPARγ KO alveolar macrophages after MWCNT 
instillation. Levels of Twist1 expression overall were higher in PPARγ KO mice than wild-type,  
an observation that coincided with previous findings showing higher levels of inflammatory mediators 
in PPARγ KO versus wild-type mice [81]. While functional studies of Twist1 are still in progress,  
the current data confirm that Twist1 may coincide with an inflammatory M1 alveolar macrophage 
phenotype in both mouse and man. 
3. Summary and Conclusions 
Human granulomatous diseases are chronic in nature and comprise a world-wide health problem.  
In many cases such as sarcoidosis, the etiology may be unknown. Efforts to study mechanisms of 
granulomatous disease have been hampered by the lack of a chronic pulmonary disease model. In 
studies of carbon nanotube toxicity, investigators have frequently reported persistent granulomatous 
structures within the lungs of experimental animals after instillation of carbon nanotubes. Based upon 
such studies, we developed a MWCNT model of chronic granulomatous lung disease which has 
proved to exhibit numerous pathophysiologic characteristics similar to those of human sarcoidosis.  
The possibility of carbon nanotube contribution to human granulomatous diseases such as sarcoidosis 
is an important environmental issue but has not been addressed previously. Overall, data from the 
chronic MWCNT model suggest that this model has a broad range of applicability for probing 
mechanisms of inflammation and granuloma persistence, as well as the potential for exploring novel 
therapeutic approaches to chronic granulomatous disease. 
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